Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms
Guido Rindi, Özgür Mete, Silvia Uccella, et al.
Endocrine Pathology (2022) Vol. 33, Iss. 1, pp. 115-154
Closed Access | Times Cited: 553

Showing 1-25 of 553 citing articles:

Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms
Özgür Mete, Bruce M. Wenig
Head and Neck Pathology (2022) Vol. 16, Iss. 1, pp. 123-142
Open Access | Times Cited: 108
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
Simron Singh, Daniel Halperin, Sten Myrehaug, et al.
The Lancet (2024) Vol. 403, Iss. 10446, pp. 2807-2817
Closed Access | Times Cited: 96
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1–G3
Francesco Panzuto, John Ramage, D. Mark Pritchard, et al.
Journal of Neuroendocrinology (2023) Vol. 35, Iss. 8
Open Access | Times Cited: 74
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours
Anja Rinke, Valentina Ambrosini, Clarisse Dromain, et al.
Journal of Neuroendocrinology (2023) Vol. 35, Iss. 6
Open Access | Times Cited: 69
A Comprehensive Review on Neuroendocrine Neoplasms: Presentation, Pathophysiology and Management
Qamar Sultana, Jill Kar, Amogh Verma, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 15, pp. 5138-5138
Open Access | Times Cited: 44
Diagnostic, Prognostic, and Predictive Role of Ki67 Proliferative Index in Neuroendocrine and Endocrine Neoplasms: Past, Present, and Future
Stefano La Rosa
Endocrine Pathology (2023) Vol. 34, Iss. 1, pp. 79-97
Open Access | Times Cited: 43
Helicobacter pylori and immunotherapy for gastrointestinal cancer
Keren Jia, Chen Yang, Yi Xie, et al.
The Innovation (2024) Vol. 5, Iss. 2, pp. 100561-100561
Open Access | Times Cited: 28
Pulmonary neuroendocrine neoplasms: the molecular landscape, therapeutic challenges, and diagnosis and management strategies
Triparna Sen, Yosuke Dotsu, Virginia Corbett, et al.
The Lancet Oncology (2025) Vol. 26, Iss. 1, pp. e13-e33
Closed Access | Times Cited: 3
Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites
Talya L. Dayton, Nicolas Alcala, Laura Moonen, et al.
Cancer Cell (2023) Vol. 41, Iss. 12, pp. 2083-2099.e9
Open Access | Times Cited: 37
Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward?
Rocio García‐Carbonero, Beatriz Antón-Pascual, Andrea Modrego, et al.
Endocrine Reviews (2023) Vol. 44, Iss. 4, pp. 724-736
Open Access | Times Cited: 31
Approach to the Patient: Insulinoma
Johannes Hofland, Julie Refardt, Richard A. Feelders, et al.
The Journal of Clinical Endocrinology & Metabolism (2023) Vol. 109, Iss. 4, pp. 1109-1118
Open Access | Times Cited: 25
Incidence and prevalence of neuroendocrine neoplasms in Norway 1993–2021
Espen Thiis‐Evensen, Raziye Boyar Cetinkaya
Journal of Neuroendocrinology (2023) Vol. 35, Iss. 4
Open Access | Times Cited: 24
Prediction of177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study
Magdalena Mileva, Gwennaëlle Marin, Hugo Levillain, et al.
Journal of Nuclear Medicine (2023) Vol. 65, Iss. 2, pp. 236-244
Open Access | Times Cited: 24
UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas
Shiqin Liu, Timothy Chai, Fernando Jose Garcia-Marques, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 2, pp. 101381-101381
Open Access | Times Cited: 17
Gastric neuroendocrine neoplasms
Giuseppe Lamberti, Francesco Panzuto, Marianne Pavel, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 13
Molecular Classification of Gastrointestinal and Pancreatic Neuroendocrine Neoplasms: Are We Ready for That?
Silvia Uccella
Endocrine Pathology (2024) Vol. 35, Iss. 2, pp. 91-106
Open Access | Times Cited: 11
Molecular subtypes of neuroendocrine carcinomas: A cross-tissue classification framework based on five transcriptional regulators
Zhanyu Wang, Chengming Liu, Sufei Zheng, et al.
Cancer Cell (2024) Vol. 42, Iss. 6, pp. 1106-1125.e8
Closed Access | Times Cited: 11
Pancreatic Cysts
Tamas A. Gonda, Djuna L. Cahen, James J. Farrell
New England Journal of Medicine (2024) Vol. 391, Iss. 9, pp. 832-843
Closed Access | Times Cited: 11
Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial
Panpan Zhang, Si Shi, Jianming Xu, et al.
European Journal of Cancer (2024) Vol. 199, pp. 113539-113539
Open Access | Times Cited: 9
Surgical Management of Gastroenteropancreatic Neuroendocrine Tumors
Lisa M. Kenney, Marybeth S. Hughes
Cancers (2025) Vol. 17, Iss. 3, pp. 377-377
Open Access | Times Cited: 1
“Cold” Somatostatin Analogs in Neuroendocrine Neoplasms: Decoding Mechanisms, Overcoming Resistance, and Shaping the Future of Therapy
Sara Massironi, Manuela Albertelli, Iderina Hasballa, et al.
Cells (2025) Vol. 14, Iss. 4, pp. 245-245
Open Access | Times Cited: 1
Incidence of gastroenteropancreatic neuroendocrine neoplasms (GEP‐NENs): An updated systematic review of population‐based reports from 2010 to 2023
Magnus Andreas Nordstrand, Dordi Lea, Jon Arne Søreide
Journal of Neuroendocrinology (2025)
Closed Access | Times Cited: 1
The efficacy of streptozotocin in managing pancreatic neuroendocrine neoplasms – A systematic review
Giulia Arrivi, Nicola Fazio, Salvatore Tafuto, et al.
Cancer Treatment Reviews (2025), pp. 102899-102899
Open Access | Times Cited: 1
Clinical Relevance of ATRX/DAXX Gene Mutations and ALT in Functioning Pancreatic Neuroendocrine Tumors
Brenna R. van ́t Veld, Wenzel M. Hackeng, Claudio Luchini, et al.
Endocrine Pathology (2025) Vol. 36, Iss. 1
Open Access | Times Cited: 1
Patterns and outcomes of current antitumor therapy for high-grade neuroendocrine neoplasms: perspective of a tertiary referral center
Philipp Melhorn, Julia Spitzer, Thomas Adel, et al.
Journal of Cancer Research and Clinical Oncology (2025) Vol. 151, Iss. 2
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top